Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
8247967
Reference Type
Journal Article
Title
Triptolide sensitizes breast cancer cells to Doxorubicin through the DNA damage response inhibition
Author(s)
Deng, Y; Li, F; He, P; Yang, Y; Yang, J; Zhang, Y; Liu, J; Tong, Y; Li, Q; Mei, X; Shu, Z; Zhao, Q
Year
2018
Is Peer Reviewed?
1
Journal
Molecular Carcinogenesis
ISSN:
0899-1987
EISSN:
1098-2744
Publisher
John Wiley and Sons Inc.
Volume
57
Issue
6
Page Numbers
807-814
Language
English
DOI
10.1002/mc.22795
Abstract
Triptolide is an active component from a Chinese herb, Tripterygium wilfordii which has been applied for treating immune-related diseases over centuries. Recently, it was reported that a variety of cancer cell lines could be sensitized to DNA-damage based chemotherapy drugs in combination with Triptolide treatment. In the present study, we show that a short time exposure (3 h) to Triptolide, which did not trigger apoptosis, could specifically increase breast cancer cells sensitivity to Doxorubicin rather than other chemotherapy drugs including Paclitaxel, Fluorouracil, and Mitomycin C. Further studies revealed Triptolide downregulated ATM expression and inhibited DNA damage response to DNA double- strand breaks. Moreover, the chemosensitization effect to Doxorubicin from Triptolide was attenuated by overexpression of ATM in breast cancer cells. Our findings suggest that Triptolide specifically chemosensitizes breast cancer cells to Doxorubicin prior to apoptosis initiation through downregulating ATM expression and inhibiting DNA damage response. © 2018 Wiley Periodicals, Inc.
Keywords
ATM; chemosensitization; DNA damage response; Triptolide
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity